Nutra Pharma to present preclinical results of RPI-78M in MS at scientific meeting

By Lisa Kerner

Erie, Pa., Feb. 9 - Nutra Pharma Corp. said that studies using RPI-78M in an animal model of Multiple Sclerosis have been accepted for presentation and publication.

RPI-78M, the lead drug candidate of Nutra Pharma's holding company, ReceptoPharm, Inc., is being studied in preclinical assays for its efficacy in treating MS, according to a company news release.

ReceptoPharm's drug, RPI-78M, proved to be very effective in preventing the onset of disability in acute and chronic models of the disease and in preventing the infiltration of immune cells into the central nervous system.

These results will be presented by Dr. Adel Mohamed at the Rocky Mountain Biotechnology Symposium at the Rose-Hulman Institute of Technology in Terre Haute, Ind., in April.

"We are very pleased to start presenting our findings within the scientific community," Rik Deitsch, chief executive officer of Nutra Pharma, said in the release.

"The positive results of the animal model as well as the strong findings from the microarray analysis support our move into phase 2 human clinical trials."

Lead researcher, Dr. Adel Mohamed, reported that the preliminary study results indicate that RPI-78M inhibited the development of acute as well as the relapsing phases of the EAE in Lewis rats. The conclusion of the report stated that it seems "within the realm of possibility" that RPI-78M may be as therapeutically efficacious as the current interferon drugs in the treatment of neurologic disease.

"It is also worth mentioning that the drug has proven to have multi-faceted properties relative to current therapies in MS," ReceptoPharm chief executive officer Paul Reid said in the release. "It demonstrates the same properties as the current MS therapies combined, in addition to having analgesic properties and minimal toxicity."

Nutra Pharma is a biopharmaceutical company specializing pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. The company is based in Boyton Beach, Fla.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.